Type of information: Private placement
Company: Y-mAbs Therapeutics (US - NY)
Investors: HBM Healthcare Investments (Switzerland), current shareholders, Sofimac Partners (France) Scopia Capital Management (US - NY)
Amount: $80 million
Funding type: private placement
- The proceeds of the financing will be used to advance the development of YmAbs portfolio of late-stage
oncology compounds including burtomab and
naxitamab, establish sales and marketing capabilities, and bolster general working capital.
- The financing will strengthen Y-mAbs Therapeutics’ balance sheet and position it for continued progress as it initiates and
completes additional clinical trials targeting a variety of cancers.
- • On November 29, 2017, Y-mAbs Therapeutics announced that it has completed an extended closing of an additional $30
million in a private equity placement, adding institutional investors Sofinnova Ventures and Scopia Capital Management to its list of shareholders. Together, with the $50 million raised in the first closing, Y-mAbs has now raised $80 million pursuant to this private placement round.
• On October 24, 2017, Y-mAbs Therapeutics announced that it has closed a private placement among HBM Healthcare Investments and its current shareholders raising $50 million.
Therapeutic area: Cancer - Oncology